165 related articles for article (PubMed ID: 8688341)
1. Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer.
Howell A; DeFriend DJ; Robertson JF; Blamey RW; Anderson L; Anderson E; Sutcliffe FA; Walton P
Br J Cancer; 1996 Jul; 74(2):300-8. PubMed ID: 8688341
[TBL] [Abstract][Full Text] [Related]
2. Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer.
Howell A; DeFriend D; Robertson J; Blamey R; Walton P
Lancet; 1995 Jan; 345(8941):29-30. PubMed ID: 7799704
[TBL] [Abstract][Full Text] [Related]
3. ICI 182,780 (Faslodex): development of a novel, "pure" antiestrogen.
Howell A; Osborne CK; Morris C; Wakeling AE
Cancer; 2000 Aug; 89(4):817-25. PubMed ID: 10951345
[TBL] [Abstract][Full Text] [Related]
4. Effects of 4-hydroxytamoxifen and a novel pure antioestrogen (ICI 182780) on the clonogenic growth of human breast cancer cells in vitro.
DeFriend DJ; Anderson E; Bell J; Wilks DP; West CM; Mansel RE; Howell A
Br J Cancer; 1994 Aug; 70(2):204-11. PubMed ID: 8054267
[TBL] [Abstract][Full Text] [Related]
5. The effects of ICI 182,780, a pure anti-oestrogen, on the hypothalamic-pituitary-gonadal axis and on endometrial proliferation in pre-menopausal women.
Thomas EJ; Walton PL; Thomas NM; Dowsett M
Hum Reprod; 1994 Nov; 9(11):1991-6. PubMed ID: 7868662
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer.
Osborne CK; Coronado-Heinsohn EB; Hilsenbeck SG; McCue BL; Wakeling AE; McClelland RA; Manning DL; Nicholson RI
J Natl Cancer Inst; 1995 May; 87(10):746-50. PubMed ID: 7563152
[TBL] [Abstract][Full Text] [Related]
7. Estrogenic effects of toremifene and tamoxifen in postmenopausal breast cancer patients.
Ellmén J; Hakulinen P; Partanen A; Hayes DF
Breast Cancer Res Treat; 2003 Nov; 82(2):103-11. PubMed ID: 14692654
[TBL] [Abstract][Full Text] [Related]
8. Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer.
DeFriend DJ; Howell A; Nicholson RI; Anderson E; Dowsett M; Mansel RE; Blamey RW; Bundred NJ; Robertson JF; Saunders C
Cancer Res; 1994 Jan; 54(2):408-14. PubMed ID: 8275477
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen.
Goss PE; Clark RM; Ambus U; Weizel HA; Wadden NA; Crump M; Walde D; Tye LM; De Coster R; Bruynseels J
Clin Cancer Res; 1995 Mar; 1(3):287-94. PubMed ID: 9815984
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic profile of intramuscular fulvestrant in advanced breast cancer.
Robertson JF; Erikstein B; Osborne KC; Pippen J; Come SE; Parker LM; Gertler S; Harrison MP; Clarke DA
Clin Pharmacokinet; 2004; 43(8):529-38. PubMed ID: 15170367
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of the tolerance and pharmacokinetics of toremifene in patients with cancer.
Kohler PC; Hamm JT; Wiebe VJ; DeGregorio MW; Shemano I; Tormey DC
Breast Cancer Res Treat; 1990 Aug; 16 Suppl():S19-26. PubMed ID: 2149280
[TBL] [Abstract][Full Text] [Related]
12. Fulvestrant: pharmacokinetics and pharmacology.
Robertson JF; Harrison M
Br J Cancer; 2004 Mar; 90 Suppl 1(Suppl 1):S7-10. PubMed ID: 15094758
[TBL] [Abstract][Full Text] [Related]
13. Hormonal effects of toremifene in breast cancer patients.
Számel I; Vincze B; Hindy I; Kerpel-Fronius S; Eckhardt S; Mäenpää J; Grönroos M; Kangas L; Sundquist H; Hajba A
J Steroid Biochem; 1990 Jun; 36(3):243-7. PubMed ID: 2142246
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer.
Robertson JF; Nicholson RI; Bundred NJ; Anderson E; Rayter Z; Dowsett M; Fox JN; Gee JM; Webster A; Wakeling AE; Morris C; Dixon M
Cancer Res; 2001 Sep; 61(18):6739-46. PubMed ID: 11559545
[TBL] [Abstract][Full Text] [Related]
15. A pure antiestrogen, ICI 182,780, stimulates the growth of tamoxifen-resistant KPL-1 human breast cancer cells in vivo but not in vitro.
Kurebayashi J; Otsuki T; Yamamoto S; Kurosumi M; Nakata T; Akinaga S; Sonoo H
Oncology; 1998 Dec; 55 Suppl 1():23-34. PubMed ID: 9852399
[TBL] [Abstract][Full Text] [Related]
16. Pure oestrogen antagonists for the treatment of advanced breast cancer.
Howell A
Endocr Relat Cancer; 2006 Sep; 13(3):689-706. PubMed ID: 16954425
[TBL] [Abstract][Full Text] [Related]
17. A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers.
Addo S; Yates RA; Laight A
Br J Cancer; 2002 Dec; 87(12):1354-9. PubMed ID: 12454761
[TBL] [Abstract][Full Text] [Related]
18. Fulvestrant ('Faslodex') in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the compassionate use programme.
Mlineritsch B; Psenak O; Mayer P; Moik M; Namberger K; Hauser-Kronberger C; Greil R
Breast Cancer Res Treat; 2007 Nov; 106(1):105-12. PubMed ID: 17295045
[TBL] [Abstract][Full Text] [Related]
19. Remission of postmenopausal breast cancer during treatment with the luteinising hormone releasing hormone agonist ICI 118630.
Plowman PN; Nicholson RI; Walker KJ
Br J Cancer; 1986 Dec; 54(6):903-9. PubMed ID: 2948537
[TBL] [Abstract][Full Text] [Related]
20. ICI 182,780, a new antioestrogen with clinical potential.
Wakeling AE; Bowler J
J Steroid Biochem Mol Biol; 1992 Sep; 43(1-3):173-7. PubMed ID: 1525058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
